Harbour BioMed, a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, has announced a multi-year, global strategic collaboration and license agreement with Bristol Myers Squibb to discover and develop next-generation multi-specific antibodies.

Under the terms of the agreement, Harbour BioMed will collaborate with Bristol Myers Squibb to advance and accelerate multi-specific antibody discovery programs. In return, Harbour BioMed could receive payments totaling $90 million, as well as development and commercial milestones of up to $1.035 billion, along with tiered royalties should Bristol Myers Squibb elect to advance all potential programs.

Jingsong Wang, MD, PhD, Founder, Chairman, and CEO of Harbour BioMed, said: “We are delighted to collaborate with Bristol Myers Squibb to advance next-generation multi-specific antibody discovery and development.”

According to Wang, the collaboration leverages the Harbour Mice fully human antibody technology platform, which facilitates the efficient discovery and development of innovative biologics with enhanced therapeutic potential.

Furthermore, the collaboration offers the possibility to utilize Harbour BioMed’s established development capabilities to accelerate programs by conducting early clinical trials in China.

Wang added, “By uniting the strengths of our platform with Bristol Myers Squibb’s expertise in drug discovery and development, we look forward to progressing these programs and delivering transformative therapies to patients worldwide.”